Reading LNTH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LNTH free→Reading LNTH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LNTH free→
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady. Earnings quality is neutral, and risk is elevated, while the sector backdrop is a headwind. Compared with sector peers, LNTH is above typical. Peer multiples imply a price about 3% below where it trades (it looks expensive on this basis); the read is fair. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $104.67. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $105 LNTH trades at 18× p/e, below its 20× p/e peer median. Our $102 fair value sits above the price; high confidence. Analysts: $89–$115. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 3% near-term growth, in line with our forecast of about 9%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.46x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.25 → $1.30 (+3.7% / 30d). 5 raised, 4 cut, 11 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 85% of analysts rate Buy.
1 PT revisions / 30d. Avg target 14.9% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$133.
How much price usually moves either way.
On a bad day, this stock has moved -$304.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,022.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Approval would support Lantheus's growth in PET imaging, a key focus area.
Confirms:FDA grants full approval for LNTH-2501 by the June 29 deadline.
Disproves:FDA denies approval or delays beyond June 29.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LNTH yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 7, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three months ended March 31, 2026. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$89.00 – $115.00 (median $98.00) · 7 analysts · as of 2026-05-27
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LNTH Lantheus Holdings | Above typical Show detailsSector percentile: 84 of 100 | full | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 74 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to prioritize revenue growth as a key strategic focus.
Enhance operating income through cost management and efficiency improvements.
Focus on increasing cash flow from operations to support strategic initiatives.
Why it matters: A drop in sector growth could impact Lantheus's performance and outlook.
Confirms:Sector revenue growth reported below 8% year over year.
Disproves:Sector revenue growth remains above 8% year over year.
Why it matters: Better operating income helps Lantheus make more money. It shows they manage costs well.
Confirms:Operating income increases to above $85M in Q2.
Disproves:Operating income remains below $80M in Q2.
Why it matters: Steady revenue growth is important. The company aims to boost its performance.
Confirms:Q2 revenue growth reported above 2% YoY.
Disproves:Q2 revenue growth below 2% YoY.
Why it matters: Higher cash from operations would show Lantheus is managing its capital well.
Confirms:Cash from operations increases by at least 10% quarter over quarter.
Disproves:Cash from operations declines or stays flat.
Why it matters: More cash from operations helps Lantheus invest in growth and pay off debt.
Confirms:Cash from operations exceeds $130M in Q2.
Disproves:Cash from operations drops below $120M in Q2.
Why it matters: The launch is expected to enhance Lantheus's market position in PET imaging.
Confirms:Successful launch of PYLARIFY TruVu as planned in Q4 2026.
Disproves:Launch is delayed or unsuccessful.
Why it matters: Higher operating income helps Lantheus make more money.
Confirms:Operating income goes above 75% of the target.
Disproves:Operating income stays below 70% of the target.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed under Item 5.07, on April 30, 2026, the shareholders of Lantheus Holdings, Inc. (the “ Company ”) approved the Company’s Amended and Restated 2026 Equity Incentive Plan (the “ A&R 2026 Equity Incentive Plan ”) which amended and restated the Company’s 2015 Equity Incentive Plan to (i) increase the number of shares of common stock reserv…
Material Modifications to Rights of Security Holders. The information set forth in
Results of Operations and Financial Condition. On February 26, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and twelve months ended December 31, 2025. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…